الطب الرئوي

بالأسفل التجارب السريرية الحالية.

غربل قائمة الدراسات هذه بالموقع والحالة وغيرها.

1. Post Approval Study for Treatment of Drug-resistant Adult Primary FSGS Using the LIPOSORBER® LA-15 System

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult and pediatric patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient is post renal transplantation. Treatment for FSGS is considered unsuccessful if the patient is unresponsive to standard therapy (e.g., at least 8 weeks of corticosteroids) and fails to achieve complete or partial remission. A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit.

    

2. Assessment of Sleep Disorder Breathing Risk in Patients with Scleroderma

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to retrospectively review the charts of 200 patients for whom overnight oximetry data, pulmonary function tests, as well as echocardiographic data have been obtained as part of routine clinical assessment. In so doing, the hope is to assess the risk of sleep disorder breathing, as evidenced by the oxygen desaturation index (ODI) on overnight oximetry assessment.

3. Rivet PVS Therapy in Group 2C

   Rochester, Minn.

   The purpose of this study is to evaluate the safety, performance, and initial clinical efficacy of the Rivet PVS therapy in patients with symptomatic pulmonary hypertension.

4. A Study of Patients Undergoing Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer to Evaluate Perioperative Circulating Tumor DNA as a Prognostic Biomarker

   Jacksonville, Fla.

   The purpose of this study is to determine the validity of employing quantitative ctDNA as a surrogate marker for pathologic treatment response in patients receiving neoadjuvant therapy for Stage IIA-IIIB NSCLC undergoing curative-intent resection. We will assess the relationship between major pathologic response (≤10% viable tumor remaining) and percent change in levels of ctDNA concentration before and after neoadjuvant therapy.

5. Creation of a Longitudinal Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

   Rochester, Minn.

   To develop a repository of blood, urine and tissue samples from patients with ILD to support future studies into the development of such biomarkers.

6. Assessment of the Mechanical Properties of Lung Parenchyma using Magnetic Resonance Elastography

   Rochester, Minn.

   The purpose of this research study is testing a new technique for measuring stiffness of the lung. This new technique is called Magnetic Resonance Elastography (MRE). In this study we will look at the stiffness measurements in humans.

7. A Study to Evaluate the Safety, Tolerability, and Determine the Optimal Dose for the Expansion Cohorts of VSV-IFNβ-NIS in Combination with Pembrolizumab in Patients with Refractory Solid Tumors

   Rochester, Minn.

   The purpose of this study is to determine the safety of VSV-IFNβ-NIS in combination with pembrolizumab, followed by expansion to examine effectiveness of combination therapy in patients with refractory Non-Small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC).

8. A Study to Assess Frailty and Its Impact on Patients with Pulmonary Hypertension

   Rochester, Minn.

   The purpose of this study is to evaluate the prevalence and effect of frailty in patients referred to pulmonary hypertension (PH) clinic at our institution.

9. A Study to Collect Medical and Personal Histories, Blood and/or Tumor Tissue Samples from Patients Who are Long-term Survivors of Lung Cancer

   Rochester, Minn.

   The purpose of this study is to collect medical and personal histories, blood and/or tumor tissue samples from patients who are long-term survivors of lung cancer. This study will help us to develop better ways to provide care and advice, develop better treatments to minimize long-term side effects, and improve the quality of life and outcome of lung cancer patients. This study will also help us to learn whether certain genes (inherited factors from your parents) increase the risk of developing or dying of lung cancer.

10. A Study to Evaluate RP1 Monotherapy and Combined with Nivolumab

    Rochester, Minn., Scottsdale/Phoenix, Ariz.

    The purpose of this study is to evaluate the dose escalation and expansion of RP1 alone and combined with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary effectiveness.

بالأسفل التجارب السريرية الحالية.

غربل قائمة الدراسات هذه بالموقع والحالة وغيرها.

1. Post Approval Study for Treatment of Drug-resistant Adult Primary FSGS Using the LIPOSORBER® LA-15 System

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult and pediatric patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient is post renal transplantation. Treatment for FSGS is considered unsuccessful if the patient is unresponsive to standard therapy (e.g., at least 8 weeks of corticosteroids) and fails to achieve complete or partial remission. A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit.

    

2. Assessment of Sleep Disorder Breathing Risk in Patients with Scleroderma

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to retrospectively review the charts of 200 patients for whom overnight oximetry data, pulmonary function tests, as well as echocardiographic data have been obtained as part of routine clinical assessment. In so doing, the hope is to assess the risk of sleep disorder breathing, as evidenced by the oxygen desaturation index (ODI) on overnight oximetry assessment.

3. Rivet PVS Therapy in Group 2C

   Rochester, Minn.

   The purpose of this study is to evaluate the safety, performance, and initial clinical efficacy of the Rivet PVS therapy in patients with symptomatic pulmonary hypertension.

4. A Study of Patients Undergoing Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer to Evaluate Perioperative Circulating Tumor DNA as a Prognostic Biomarker

   Jacksonville, Fla.

   The purpose of this study is to determine the validity of employing quantitative ctDNA as a surrogate marker for pathologic treatment response in patients receiving neoadjuvant therapy for Stage IIA-IIIB NSCLC undergoing curative-intent resection. We will assess the relationship between major pathologic response (≤10% viable tumor remaining) and percent change in levels of ctDNA concentration before and after neoadjuvant therapy.

5. Assessment of the Mechanical Properties of Lung Parenchyma using Magnetic Resonance Elastography

   Rochester, Minn.

   The purpose of this research study is testing a new technique for measuring stiffness of the lung. This new technique is called Magnetic Resonance Elastography (MRE). In this study we will look at the stiffness measurements in humans.

6. Creation of a Longitudinal Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

   Rochester, Minn.

   To develop a repository of blood, urine and tissue samples from patients with ILD to support future studies into the development of such biomarkers.

7. A Study to Evaluate the Safety, Tolerability, and Determine the Optimal Dose for the Expansion Cohorts of VSV-IFNβ-NIS in Combination with Pembrolizumab in Patients with Refractory Solid Tumors

   Rochester, Minn.

   The purpose of this study is to determine the safety of VSV-IFNβ-NIS in combination with pembrolizumab, followed by expansion to examine effectiveness of combination therapy in patients with refractory Non-Small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC).

8. A Study to Assess Frailty and Its Impact on Patients with Pulmonary Hypertension

   Rochester, Minn.

   The purpose of this study is to evaluate the prevalence and effect of frailty in patients referred to pulmonary hypertension (PH) clinic at our institution.

9. A Study to Collect Medical and Personal Histories, Blood and/or Tumor Tissue Samples from Patients Who are Long-term Survivors of Lung Cancer

   Rochester, Minn.

   The purpose of this study is to collect medical and personal histories, blood and/or tumor tissue samples from patients who are long-term survivors of lung cancer. This study will help us to develop better ways to provide care and advice, develop better treatments to minimize long-term side effects, and improve the quality of life and outcome of lung cancer patients. This study will also help us to learn whether certain genes (inherited factors from your parents) increase the risk of developing or dying of lung cancer.

10. A Study to Evaluate RP1 Monotherapy and Combined with Nivolumab

    Rochester, Minn., Scottsdale/Phoenix, Ariz.

    The purpose of this study is to evaluate the dose escalation and expansion of RP1 alone and combined with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary effectiveness.